Murali Arvind R, Patil Sanjeev, Phillips Kirk T, Voigt Michael D
1 Division of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA. 2 Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA. 3 Department of Health Management and Policy, University of Iowa College of Public Health, Iowa City, IA. 4 Organ Transplant Center, Division of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA.
Transplantation. 2017 Aug;101(8):e249-e257. doi: 10.1097/TP.0000000000001730.
Locoregional therapy with curative intent (CLRT) followed by salvage liver transplantation (SLT) in case of hepatocellular carcinoma (HCC) recurrence is an alternative to primary liver transplantation (LT) in selected patients with HCC.
We performed a systematic review and meta-analysis of studies comparing the survival of patients treated with CLRT versus LT, stratified by the stage of liver disease, extent of cancer, and whether SLT was offered or not.
We included 48 studies involving 9835 patients (5736 patients with CLRT and 4119 patients with primary LT). Five-year overall survival (OS) and disease-free survival (DFS) was worse for all categories of CLRT combined, than for primary LT (odds ratio [OR] for OS, 0.59; 95% confidence interval [CI], 0.48-0.71; P < 0.01). However, 5-year OS for CLRT and primary LT was not significantly different among patients with (i) Child-A cirrhosis and (ii) single HCC lesion, although DFS was worse. When SLT was offered after CLRT, intention-to-treat analysis showed no significant difference in 5-year OS (OR, 1.0; 95% CI, 0.6-1.7) between CLRT-SLT and primary LT, though noninferiority could not be shown. Only 32.5% patients with HCC recurrence after CLRT actually received SLT, as the rest were not medically eligible. Thus, the DFS was worse with CLRT-SLT (OR, 0.31; 95% CI, 0.2-0.6) compared with LT.
CLRT-SLT may be offered as first-line therapy to patients with HCC and well-compensated cirrhosis instead of primary LT because it may lead to better utilization of donor liver. However, a large proportion of patients with HCC recurrence after CLRT may not be candidates for SLT.
对于肝细胞癌(HCC)患者,以治愈为目的的局部区域治疗(CLRT),若出现HCC复发则进行挽救性肝移植(SLT),是部分特定HCC患者原发性肝移植(LT)的替代方案。
我们对比较CLRT与LT治疗患者生存率的研究进行了系统评价和荟萃分析,根据肝病分期、癌症范围以及是否提供SLT进行分层。
我们纳入了48项研究,涉及9835例患者(5736例接受CLRT,4119例接受原发性LT)。所有CLRT类别患者的5年总生存率(OS)和无病生存率(DFS)均低于原发性LT(OS的比值比[OR]为0.59;95%置信区间[CI]为0.48 - 0.71;P < 0.01)。然而,在(i)Child - A级肝硬化和(ii)单个HCC病灶的患者中,CLRT和原发性LT的5年OS无显著差异,尽管DFS较差。当CLRT后提供SLT时,意向性分析显示CLRT - SLT与原发性LT之间的5年OS无显著差异(OR为1.0;95% CI为0.6 - 1.7),但未显示出非劣效性。CLRT后HCC复发的患者中只有32.5%实际接受了SLT,其余患者不符合医学条件。因此,与LT相比,CLRT - SLT的DFS更差(OR为0.31;95% CI为0.2 - 0.6)。
CLRT - SLT可作为HCC合并代偿良好肝硬化患者的一线治疗方案,而非原发性LT,因为它可能会更好地利用供体肝脏。然而,CLRT后HCC复发的患者中很大一部分可能不适合进行SLT。